€1.6m grant supports drug discovery in metabolic diseases

""

Confo Therapeutics has been awarded a €1.6 million grant from Flanders Innovation & Entrepreneurship (VLAIO).

The two-year grant will be used to expand Confo’s R&D efforts in the discovery of new medicines targeting Class B G protein-coupled receptors (GPCRs) using its patent-protected technology platform.

Class B GPCRs are recognised as important targets for new medicines, particularly in chronic endocrine and metabolic diseases.

Cedric Ververken, CEO of Confo Therapeutics, commented: “Receiving this additional VLAIO grant will strengthen our existing small molecule and antibody discovery efforts on high-value Class B GPCRs, which further paves the way to unlock new treatments for a range of endocrine and metabolic indications including obesity. We are grateful to VLAIO for its continued support, which will bolster our capabilities in Class B GPCR drug discovery and development.”

Confo’s platform includes its ConfoBody and ConfoChimer technologies. ConfoBodies are novel VHH domains which stabilise GPCRs in pharmacological states of interest by binding to their intracellular surface. ConfoChimer technology enables universal ConfoBodies to be used across the GPCR superfamily.

Christel Menet, CSO of Confo Therapeutics, added: “Despite advances made with peptide-based treatments, the need for improved molecules capable of targeting Class B GPCRs for the treatment of endocrine and metabolic diseases remains high. Our platform has already been proven on various targets including orphan GPCRs and Class B GPCRs, and with VLAIO’s support we will be able to accelerate our efforts to further unlock valuable targets in obesity and related metabolic indications.”

Diana Spencer, Senior Digital Content Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free